Literature DB >> 8794825

A vascular modulator, hepatocyte growth factor, is associated with systolic pressure.

Y Nakamura1, R Morishita, S Nakamura, M Aoki, A Moriguchi, K Matsumoto, T Nakamura, J Higaki, T Ogihara.   

Abstract

Endothelial cells are known to secrete various antiproliferative and vasodilating factors, such as nitric oxide and natriuretic peptides. The presence of endothelial dysfunction, well known in hypertensive individuals, potentially results in the development and progression of atherosclerosis. Therefore, it is important to know the factors that might influence endothelial cell growth. We examined the mitogenic actions of hepatocyte growth factor (HGF) on human endothelial and vascular smooth muscle cells. Exogenously added human recombinant HGF stimulated endothelial but not vascular smooth muscle cell growth in a dose-dependent manner. We also compared the mitogenic action of HGF with that of basic fibroblast growth factor and vascular endothelial growth factor. Interestingly, the mitogenic action of HGF on endothelial cells was greater than the actions of basic fibroblast growth factor and vascular endothelial growth factor, whereas basic fibroblast growth factor but not HGF and vascular endothelial growth factor stimulated vascular smooth muscle cell growth. Given the characteristics of HGF as an endothelium-specific growth factor, we evaluated the relationship of circulating HGF and blood pressure in normotensive and hypertensive subjects. Serum HGF concentration has been reported to be elevated in response to organ damage, such as in hepatitis and nephritis, and recent findings show that HGF may play an important role in tissue regeneration. We hypothesized that HGF might contribute to the protection or repair of vascular endothelial cells. If so, serum HGF level might be elevated in response to endothelial cell damage induced by hypertension. To test this hypothesis, we measured serum levels of HGF, lipoprotein(a), plasminogen activator inhibitor-1, tissue plasminogen activator, total cholesterol, and blood pressure in 41 normotensive and hypertensive subjects without liver, kidney, or lung damage. Serum HGF concentration was significantly correlated with systolic pressure (P < .01, r = .43) but not diastolic pressure. Serum HGF concentration in hypertensive subjects was significantly higher than in normotensive subjects. None of the other factors showed any correlation with blood pressure. We have demonstrated that HGF is an endothelium-specific growth factor whose serum concentration is significantly associated with systolic pressure. These results suggest that HGF secretion might be elevated in response to high blood pressure as a counterregulatory system against endothelial dysfunction.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8794825     DOI: 10.1161/01.hyp.28.3.409

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  25 in total

1.  Proliferation and tube formation of periodontal endothelial cells.

Authors:  Etsuko Sato; Hisashi Hashimoto; Hisahiro Kamoi; Toshiaki Tachibana; Hiroshi Ishikawa; Kyuichi Kamoi
Journal:  Hum Cell       Date:  2005-06       Impact factor: 4.174

2.  Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus.

Authors:  K Shinoda; S Ishida; S Kawashima; T Wakabayashi; T Matsuzaki; M Takayama; K Shinmura; M Yamada
Journal:  Br J Ophthalmol       Date:  1999-07       Impact factor: 4.638

3.  Serum Hepatocyte Growth Factor Is Probably Associated With 3-Month Prognosis of Acute Ischemic Stroke.

Authors:  Zhengbao Zhu; Tan Xu; Daoxia Guo; Xinfeng Huangfu; Chongke Zhong; Jingyuan Yang; Aili Wang; Chung-Shiuan Chen; Yanbo Peng; Tian Xu; Jinchao Wang; Yingxian Sun; Hao Peng; Qunwei Li; Zhong Ju; Deqin Geng; Jing Chen; Yonghong Zhang; Jiang He
Journal:  Stroke       Date:  2018-01-10       Impact factor: 7.914

4.  Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization.

Authors:  James Richards; Khatuna Gabunia; Sheri E Kelemen; Farah Kako; Eric T Choi; Michael V Autieri
Journal:  J Mol Cell Cardiol       Date:  2014-11-08       Impact factor: 5.000

5.  Hepatocyte growth factor and the risk of ischemic stroke developing among postmenopausal women: results from the Women's Health Initiative.

Authors:  Swapnil N Rajpathak; Tao Wang; Sylvia Wassertheil-Smoller; Howard D Strickler; Robert C Kaplan; Aileen P McGinn; Rachel P Wildman; Daniel Rosenbaum; Thomas E Rohan; Philipp E Scherer; Mary Cushman; Gloria Y F Ho
Journal:  Stroke       Date:  2010-03-04       Impact factor: 7.914

6.  Heparin-mediated selective release of hepatocyte growth factor in humans.

Authors:  P B Salbach; M Brückmann; O Turovets; J Kreuzer; W Kübler; I Walter-Sack
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

7.  Hepatocyte growth factor gene-modified bone marrow-derived mesenchymal stem cells transplantation promotes angiogenesis in a rat model of hindlimb ischemia.

Authors:  Guan-Hua Su; Yu-Fei Sun; Yong-Xin Lu; Xin-Xin Shuai; Yu-Hua Liao; Qi-Yun Liu; Jun Han; Ping Luo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-08-01

8.  Production of hepatocyte growth factor during acute myocardial infarction.

Authors:  Y Zhu; Y Hojo; U Ikeda; K Shimada
Journal:  Heart       Date:  2000-04       Impact factor: 5.994

9.  Osteonecrosis of the femoral head: treatment with ancillary growth factors.

Authors:  Matthew T Houdek; Cody C Wyles; Rafael J Sierra
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 10.  Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.

Authors:  Hiroyuki Konya; Masayuki Miuchi; Kahori Satani; Satoshi Matsutani; Taku Tsunoda; Yuzo Yano; Tomoyuki Katsuno; Tomoya Hamaguchi; Jun-Ichiro Miyagawa; Mitsuyoshi Namba
Journal:  World J Diabetes       Date:  2014-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.